Connect with us

NEWS

The First In-Body CRISPR Drug Is a Liver Knockout

Lonvo-z nears a March FDA ruling as the first in-body CRISPR drug, a liver knockout for hereditary angioedema, not a test of editing everywhere.

Published

on

Intellia Therapeutics said a single 50 mg CRISPR infusion cut hereditary angioedema attacks by 87 percent versus placebo, and the FDA will decide by March 10, 2027. If the agency says yes, lonvoguran ziclumeran, or lonvo-z, becomes the first CRISPR medicine that edits genes inside the body. It can do that because the target sits in the liver, and people can live without the protein it shuts off.

Four-Year Data Hold After One Infusion

The global Phase 3 trial, called HAELO, enrolled 80 people aged 16 and older with Type 1 or Type 2 disease in nine months and tested one 50 mg dose against placebo. For weeks 5 to 28, mean monthly attacks fell to 0.26 on lonvo-z from 2.10 on placebo, an 87 percent drop (p<0.0001). Those figures, with quality-of-life scores, went into a New England Journal of Medicine paper by Danny Cohn of Amsterdam University Medical Center and colleagues (volume 395, pages 1471 to 1482, 2026).

HAELO PRIMARY RESULTS

Measure (weeks 5 to 28) Lonvo-z Placebo
Mean monthly attacks 0.26 2.10
Cut versus placebo 87% –
Attack-free and therapy-free 62% 11%
Mean monthly attacks needing on-demand drugs 0.19 1.79
Mean monthly moderate or severe attacks 0.11 1.23
AE-QoL score change to week 28 -23.51 -6.47

As of the February 10, 2026 cutoff, every HAELO patient who got lonvo-z at the start, or after crossing over at week 28, was off long-term prevention drugs. All treatment-emergent events in the lonvo-z arm were mild or moderate. None were serious. The events seen more often than on placebo were infusion-related reactions, headache, fatigue, back pain, and upper respiratory tract infection.

On November 12, 2026, ahead of talks in Phoenix at the American College of Allergy, Asthma and Immunology meeting, Intellia added longer follow-up. An integrated look found 89 percent fewer attacks across 93 patients who received 50 mg in Phase 1/2 or HAELO, measured against each person’s own baseline through follow-up that reached four years in the earliest cases. Ninety-seven percent never started long-term prevention after the drip. All 93 were off those drugs at the last visit.

The four-year monthly claim is narrower than the pooled 89 percent. In the 32-person Phase 1/2 group, at least 90 percent were attack-free in each month after the first year, with follow-up out to four years, Emel Aygören-Pürsün of University Hospital Frankfurt reported. Thirty-one of those 32 people were still in long-term follow-up. Mean plasma kallikrein fell 84 percent by week 4 and stayed down in that early group. The chance of starting a stretch longer than six months with no attacks and no prevention drugs rose from 81 percent at six months to 93 percent at 24 months.

Among HAELO patients who had been on long-term prevention, monthly attacks fell 81 percent after lonvo-z compared with that prior regimen. Aleena Banerji of Harvard Medical School and Massachusetts General Hospital presented the 93-patient pool. Most of those 93 have months of follow-up, not years. The four-year attack-free rate still sits on the open-label 32.

It’s very reassuring. That’s what you’re supposed to see.

Jonathan Bernstein, hereditary angioedema specialist and lonvo-z trial investigator, University of Cincinnati

Bernstein was talking about the four-year biomarker and attack curves, which is what a one-time liver edit is supposed to produce if the patch holds as liver cells divide.

Why Hereditary Angioedema Was the First Target

HAE causes sudden swelling in skin, gut, and airway. Throat attacks can kill. Intellia estimates the condition affects one in 50,000 people. A U.S. Hereditary Angioedema Association analysis, built from insurance claims and specialist review because the billing code is messy, put nearly 10,000 people diagnosed with HAE in the United States, counting all types, not only C1-inhibitor deficiency.

Lonvo-z uses CRISPR-Cas9 to inactivate KLKB1, the gene for prekallikrein, a liver protein that feeds the kallikrein-kinin cascade and bradykinin-driven leaks from blood vessels. Kallikrein blockade is already how several licensed prevention drugs work. The difference is permanence. Intellia wraps messenger RNA for the CRISPR tools in fatty particles, infuses them, and lets the liver take them up. The visit is one outpatient day.

That is why HAE came first. Lipid particles used for mRNA already dump their cargo in hepatocytes. Prekallikrein is made there. People born with very little of it can live. A modeling poster from Intellia argued that an 85 percent drop in prekallikrein brings peak free kallikrein and bradykinin near the normal range, so an 84 percent knockdown is not a round number pulled from a wish list. The FDA already knows this pathway from shots and daily pills. The agency is being asked to accept a one-time cut instead of a lifetime of suppression.

Doctors cannot pull the edited cells out afterward and throw away the bad ones. Off-target cuts, if they happen, stay. Recipients can also react to the particles or to Cas9. Those are the in-body tradeoffs that ex vivo programs were built to avoid.

Casgevy Still Means Taking the Cells Out

The only CRISPR therapy the FDA has cleared is Casgevy (exagamglogene autotemcel), from Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle cell disease and transfusion-dependent beta thalassemia. It was first approved on December 8, 2023, for people 12 and older. On July 1, 2026, the agency expanded Casgevy for children as young as 2, adding about 5,500 eligible children in the United States, Vertex said. Vertex set the U.S. list price at $2.2 million.

WHAT CASGEVY STILL REQUIRES

  • A custom lot: Blood stem cells leave the patient, get edited in a lab, and come back only to that person.
  • Chemotherapy: Conditioning clears marrow so the edited cells can take hold.
  • Hospital time: The process is measured in weeks, not a single clinic day.
  • A screen: Unwanted edits can be checked in the dish before the cells go back in.

Lonvo-z skips that chain. There is no autologous manufacturing slot and no chemo. There is also no dish in which to discard a badly edited cell. Casgevy proved CRISPR can be a licensed drug. It did not prove that dripping Cas9 into a person is the same act.

A Related CRISPR Infusion Left One Patient Dead

Intellia’s other late-stage in-body program, nexiguran ziclumeran (nex-z), uses the same liver-particle logic to inactivate TTR, the gene for transthyretin, in people with ATTR amyloidosis. Regeneron Pharmaceuticals is the collaborator. The dose in Phase 3 is a single 55 mg infusion. MAGNITUDE is a roughly 1,200-person, 2:1 randomized trial in ATTR cardiomyopathy. MAGNITUDE-2 is a roughly 60-person, 1:1 trial in hereditary ATTR polyneuropathy.

THE NEX-Z HOLD

  1. October 29, 2025: The FDA places clinical holds on MAGNITUDE and MAGNITUDE-2 after a MAGNITUDE patient develops Grade 4 liver-enzyme and bilirubin rises that meet the protocol pause rule. The participant later dies.
  2. January 2026: The agency lifts the MAGNITUDE-2 hold after Intellia adds closer liver-lab checks and short-term steroid guidance if enzymes rise soon after dosing.
  3. March 2, 2026: The FDA removed the clinical hold on MAGNITUDE and adds exclusions for certain liver abnormalities, recent heart instability, and ejection fraction below 25 percent at screening.
  4. November 4, 2026: Intellia completes MAGNITUDE-2 enrollment.

John Leonard, Intellia’s chief executive, said the company had aligned with the FDA on a path that lets nex-z keep going in a broad ATTR-CM group. A later genomic review of more than 600 nex-z trial samples found the highest liver-enzyme spikes in people carrying one specific HLA allele. Investigators now get those genotyping results for people already in, or entering, the Phase 3 studies. That finding is a clue, not a clean bill. HAELO reported no serious events on lonvo-z. MAGNITUDE reported a death on a related liver CRISPR drip. They are different genes, different patients, and a 5 mg dose gap. They are still the same delivery idea.

Patients Already Pay for Lifelong Prevention

HAE is not an untreated market waiting for CRISPR. People already cycle through C1-inhibitor replacement, daily oral kallikrein blockade, and injected antibodies. Breakthrough attacks still happen. Intellia’s own disease summary notes twice-weekly intravenous or subcutaneous dosing, or a daily pill, and says breakthroughs occur anyway. Lonvo-z’s commercial pitch is that one drip ends that calendar.

The Institute for Clinical and Economic Review published 2025 U.S. list prices for three drugs cleared that year. Intellia has not named a lonvo-z price.

HAE DRUGS ALREADY ON THE SHELF

Product How it is given 2025 U.S. list price (ICER) Status
Lonvo-z One 50 mg infusion Not announced FDA target March 10, 2027
Andembry (garadacimab), CSL Monthly autoinjector $618,583 a year Approved 2025
Dawnzera (donidalorsen), Ionis Injection every 4 or 8 weeks $689,544 a year Approved 2025
Ekterly (sebetralstat), KalVista Oral, on demand $200,640 a year Approved 2025

Those list prices are not what every insurer pays, and Takhzyro, Orladeyo, and plasma C1 inhibitors sit outside that 2025 trio. They still show what a one-time edit is walking into: yearly bills that already run into the high six figures for prevention, plus on-demand drugs for the attacks that leak through. Payers will compare a CRISPR invoice with those annuities. Patients will compare one clinic day with needles and prior authorizations that never stop. Intellia has not said which side of that math it will publish first.

What the FDA Will Decide by March 10

On September 8, 2026, Intellia said the FDA had accepted the biologics license application, granted Priority Review and a March 10, 2027 action date, and advised that it is not currently planning an advisory committee. Lonvo-z already holds five special designations: FDA Orphan Drug and Regenerative Medicine Advanced Therapy, a U.K. Innovation Passport, EMA PRIME, and European Commission orphan status. A rolling file was possible because of the RMAT tag. That is not an approval.

WHAT WE KNOW

  • The clock: Priority Review, target action March 10, 2027, no advisory committee currently planned.
  • The file: HAELO in the New England Journal of Medicine, 87 percent fewer attacks versus placebo, kallikrein down 84 percent in the earliest patients out to four years.
  • The use: Adults and adolescents 16 and older with Type 1 or Type 2 HAE, one 50 mg outpatient infusion.

WHAT IS UNCONFIRMED

  • The decision: Clearance, a complete-response letter, or extra questions on durability and off-target edits.
  • The price: No U.S. list price has been posted.
  • The label: Whether FDA language will describe a functional cure, attack reduction, or something in between.
  • The overlap: How the HAELO safety file will be read next to the nex-z death.

Leonard told investors on November 12, 2026, that approval would make lonvo-z the world’s first in vivo CRISPR therapy. In the September application note he said the company believes lonvo-z could change how HAE is treated. Joshua Jacobs, a HAELO investigator, called HAE unpredictable, a source of profound disability, and a risk for fatal attacks. Those are the claims the review staff will weigh against a 32-person four-year tail and a related program that had to stop, then restart, after a liver injury.

Intellia Is Staffing a Launch Before the Vote

Intellia, based in Cambridge, Massachusetts, has already built field medical, reimbursement, and strategic-accounts teams and has been meeting U.S. HAE centers. A November 5, 2026 business update said commercial readiness work is on track for a planned first-quarter 2027 launch if the product is cleared. Cash, cash equivalents, and marketable securities were $628.4 million as of June 30, 2026, after a $195 million April offering, a total the company said should fund operations at least into 2028, not counting lonvo-z sales.

HAELO is a strong rare-disease file on a pathway regulators already understand. The four-year kallikrein curve in the first patients is the durability argument a one-time edit has to make. The ATTR death is the in-body risk the same platform still carries. March 10, 2027, is a date for hereditary angioedema. It is not a verdict on dripping CRISPR into every liver.

Disclaimer: This article is news reporting and analysis of company statements, trial figures, and regulatory dates. It is informational only and is not medical advice, a treatment recommendation, or investment advice. Readers considering hereditary angioedema care, gene-editing therapy, or related clinical decisions should consult a qualified physician, and readers considering securities of Intellia or its peers should consult a licensed financial adviser. Figures, trial statuses, and the FDA timetable reflect the cited company filings and scientific accounts as of the sources’ dates and may change if the agency, the sponsor, or later follow-up revises them.

Harry is the editor of SOMALI UPDATE, an independent title he owns and runs. Ten years in journalism, from reporter to editor, have settled into a set of verification habits he applies to every story. A quote is checked against the recording or transcript it came from. A statement attributed to an organisation is confirmed on that organisation's own channels before it is repeated. A figure is traced to the dataset or filing that first published it, and a photograph is checked for when and where it was actually taken. If any of those checks fails, the claim is left out or clearly marked as unconfirmed. Those habits cover the whole site, which reports news, business, technology, science and sports along with entertainment, lifestyle, travel, auto and gaming for readers around the world. Product claims in the technology, auto and gaming pages are tested in use where Harry can get his hands on the product. Corrections are published under a public policy and noted on the article. Readers who want to question a fact can write to support@somaliupdate.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending